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Abstract
Objectives—The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease 
activity index developed as a clinical trial endpoint. More recently, practice guidelines have 
recommended the use of PUCAI in routine clinical care. We therefore sought to evaluate the 
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feasibility, validity and responsiveness of PUCAI in a large, diverse collection of pediatric 
gastroenterology practices.
Methods—We extracted data from the two most recent encounters for patients with ulcerative 
colitis in the ImproveCareNow registry. Feasibility was determined by the percent of patients for 
whom all PUCAI components were recorded, validity by correlation of PUCAI scores across 
Physician Global Assessment (PGA) categories, and responsiveness to change by the correlation 
between the change in PUCAI and PGA scores between visits.
Results—2503 patients were included (49.5% male, age 15.2±4.1 years, disease duration 3.7±3.2 
years). All items in the PUCAI were completed for 96% of visits. PUCAI demonstrated excellent 
discriminatory ability between remission, mild and moderate disease; discrimination between 
moderate and severe disease was less robust. There was good correlation with PGA [r=0.76 
(p<0.001), weighted kappa k=0.73 (p<0.001)]. The PUCAI change scores correlated well with 
PGA change scores (p<0.001). Test-retest reliability of the PUCAI was good (intra-class 
correlation coefficient=0.72 [95% CI 0.70–0.75], p<0.001). Guyatt’s responsiveness statistic was 
1.18 and the correlation of ΔPUCAI with ΔPGA was 0.69 (p<0.001).
Conclusions—The PUCAI is feasible to use in routine clinical settings. Evidence of its validity 
and responsiveness support its use as a clinical tool for monitoring disease activity for patients 
with ulcerative colitis.
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inflammatory bowel disease; ulcerative colitis; pediatric; PUCAI
Introduction
Ulcerative colitis (UC) is a chronic, relapsing inflammatory disorder affecting the colon. In 
routine clinical practice, gastroenterologists often use the Physician Global Assessment 
(PGA) as a way to classify disease activity. PGA is based on thephysician’s subjective 
clinical impression of the patient, taking into account factors such as abdominal pain, stool 
characteristics, fatigue, abdominal tenderness, and available lab tests. PGA is classified as 
either remission (inactive), mild, moderate or severe. The Pediatric Ulcerative Colitis 
Activity Index (PUCAI)1 was developed to provide a more objective assessment of disease 
activity in ulcerative colitis (the PUCAI components and corresponding scoring is illustrated 
in Table 1). The PUCAI underwent a rigorous development process, and has been shown to 
be a valid, responsive tool. Indeed, the PUCAI has been widely-adopted by clinical 
researchers as a non-invasive measure of disease activity2–7.
Use of the PUCAI has also been recommended in the routine clinical management of 
pediatric patients with UC, and has been incorporated into recent clinical guidelines2,8. 
Although the use of PUCAI has been evaluated in single-center and small multi-center 
research studies1,5,9–12, little is known about the feasibility and performance of PUCAI 
when used in routine clinical practice. We therefore sought to evaluate the feasibility, 
validity and responsiveness to clinical change of the PUCAI in a large, diverse collection of 
pediatric gastroenterology practices. The specific objectives of this study were to: 1.) 
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evaluate the feasibility of using PUCAI in routine clinical practice settings, 2.) evaluate the 
cross-sectional and longitudinal associations between PUCAI and PGA.
Materials and Methods
ImproveCareNow (ICN) is a network of pediatric gastroenterology practices established in 
2007 to improve the health and healthcare of children and adolescents with IBD. The ICN 
registry contains demographic, disease and treatment data collected prospectively and 
longitudinally during outpatient encounters. Data collection at each center is embedded into 
the clinical workflow, generally through the use of a paper-based or electronic health record 
(EHR) clinic template. During the time of this study, a study coordinator at most sites 
subsequently entered this data into a web-based registry form. At a small number of centers, 
data from the EHR template was Extracted, Transformed, and Loaded (ETL) into the 
registry. Patients were diagnosed and managed according to the usual practice of the 
primary gastroenterologist and quality improvement methodologies were applied within 
centers.
In this retrospective analysis, we extracted data from the two most recent encounters for all 
patients with ulcerative colitis in the ICN registry (September 2006 to December 2012). 
Data elements used in this study included basic demographics, disease duration, disease 
extent as defined by Paris classification,13 laboratory studies (hematocrit, erythrocyte 
sedimentation rate (ESR), c-reactive protein (CRP), albumin), PGA, medications and 
PUCAI measurement components (abdominal pain, rectal bleeding, consistency of most 
stools, the total number of stools, nocturnal stools, and activity level).
Feasibility
The feasibility is a measure used to determine the practicality of collecting the PUCAI 
components. It was determined by the percent of patients for whom all PUCAI components 
were recorded at the most recent visit.
Validity
The validity is the extent to which a tool measures what it claims to measure in a real world 
setting. To assess validity, we first evaluated the distribution of PUCAI scores across 
categories (remission, mild, moderate, severe) of the Physician Global Assessment (PGA) 
using boxplots and then compared the differences using the Kruskal-Wallis test. We then 
calculated Pearson’s correlation coefficient to evaluate the correlation between PUCAI and 
PGA. Finally, to measure the agreement between the disease severity captured by PUCAI 
and that captured by PGA, we used the percentage of agreement and Cohen’s Kappa 
coefficients, based on the following published PUCAI cut-points: remission <10, mild 10–
34, moderate 35–64, and severe 65–85.1,9 Specifically, the absolute agreement was assessed 
using the unweighted Kappa; whereas, a Kappa coefficient with quadratic weighting was 
calculated for the relative concordance between the two measures.
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The responsiveness of an instrument is its ability to detect minimal clinically important 
differences and is directly related to the magnitude of that change14–16. The responsiveness 
in this study reflects the extent to which PUCAI changes in relation to a corresponding 
change in PGA (reference measure) over time. A successful approach to defining the change 
in PGA for longitudinal analysis has been previously documented9,17,18. A small change in 
PGA between baseline and repeated visits was defined by a change in one category (e.g. 
severe to moderate, mild to moderate, mild to remission). A moderate change in PGA was 
defined as a change in 2 categories (e.g. moderate to remission, mild to severe), and a large 
change as 3 categories (e.g. severe to remission).18
We evaluated the distribution of the change in PUCAI according to the change in PGA using 
boxplots, and compared PUCAI across change in PGA subgroups using the Kruskal-Wallis 
test. We then assessed the test-retest reliability of the assigned PUCAI values of each visit 
for patients whose disease assessment (PGA) remained unchanged18. This was assessed 
using the intra-class correlation coefficient (ICC) using ANOVA. The PUCAI change score 
was determined by subtracting the follow-up PUCAI score from the previous visit PUCAI 
score.
Different statistical methods were used to evaluate the responsiveness of PUCAI. Following 
the distributional-based approach, we calculated Guyatt’s responsiveness statistic with the 
minimal important difference (MID). The MID was set as the PUCAI change score 
associated with the highest sensitivity and specificity to distinguish changed versus 
unchanged patients.10,14 Additionally, we used Pearson’s correlation coefficients to evaluate 
associations between change in PUCAI score and change in PGA.
A p-value of 0.05 was used to determine significance. Analyses were performed using R 
version 2.14.1. The analysis of this data set was considered exempt by the Institutional 
Review Board at Children’s Hospital of Philadelphia.
Results
Our study population included 2503 pediatric patients with ulcerative colitis from 35 
centers. The population was composed of 49.4% males (n = 1237), with a mean age of 15.2 
± 4.1years (median 15.9 years), and mean disease duration of 3.7 ± 3.2 years. Additional 
demographic and clinical details are provided in Table 2.
Feasibility
Over 96% of visits contained all six required components to calculate a PUCAI, with 
approximately 2% missing only 1 component and 2% missing 2 or more components. 
(Supplemental Table 1).
Validity
The study sample that contributed to the validity analysis consisted of patients with both a 
recorded PUCAI and PGA for the visit (n=2355, 94%). Of these patients, 1654 (70%) had a 
PUCAI <10 (remission), 496 (21%) had a PUCAI between 10–34 (mild disease activity), 
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176 (8%) had a PUCAI between 35–64 (moderate disease activity), and 29 (1%) had a 
PUCAI between 65–85 (severe disease activity). The PUCAI demonstrated discriminatory 
ability between disease classification based on PGA (Figure 1, p < 0.001). There was good 
correlation with PGA [r = 0.76 (p < 0.001), agreement 77%, Cohen’s unweighted kappa 
statistic k = 0.53 (p< 0.001) and weighted kappa k = 0.73 (p < 0.001)].
Responsiveness
A total of 1874 patients had both PUCAI and PGA recorded for the two most recent visits 
(of the 2355 patients, 481 (20%) did not have a prior visit). The mean number of days 
between the current and previous visit was 166 days (SD ± 149, median = 133, IQR 75 to 
198, range 1 to 1846). The change in PUCAI scores differentiated well the different 
categories of change in PGA (Figure 2; Table 3; Kruskal-Wallis with degree of freedom 6, p 
< 0.001).
There were 1236 patients whose disease severity (judged by PGA) at the most recent and the 
previous visit remained unchanged. For these 1236 patients, the distribution of the PGA-
based disease severity was 1040 (84%) in remission, 145 (12%) with mild disease activity, 
44 (4%) with moderate disease activity and 7 (<1%) with severe disease activity. The test-
retest reliability of the PUCAI (median change in PUCAI is 0) was good (ICC = 0.72 [95% 
CI 0.70–0.75], p < 0.001). We defined improved and worsened disease activity as at least a 
moderate change. Stable was defined as a small change or no change. The MID of small 
change in PUCAI, which was used to calculate the responsiveness statistic (Table 3), was 10 
points (for improvement: sensitivity 78.4%, specificity 77.7%; area under the ROC curve 
0.819 [95% CI, 0.790 – 0.848]; for worsening: sensitivity 82.7%, specificity 80.3% and area 
under the ROC curve 0.852 [95% CI, 0.822 – 0.882]). The correlation of PUCAI change 
scores with PGA change scores was 0.69 (p < 0.001).
Discussion
This is the first large-scale, multicenter evaluation of the feasibility, validity and 
responsiveness to change of the PUCAI in relation to PGA in a simulated-routine clinical 
practice setting. The feasibility of using PUCAI in an outpatient clinical practice setting was 
excellent. Over 96% of visits contained all six required components to calculate a PUCAI. 
Via several analytic methods, we were able to demonstrate high correlation of the PUCAI 
with PGA. The test-retest reliability of the PUCAI was also quite good. This study extends 
the foundational work completed by Turner, et al by including a large sample size and 
diversity of practice sites (approximately 2000 patients from 35 centers).18 The PUCAI 
differentiated very well among the four PGA-based disease severity categories, with fairly 
clear separation between disease categories. The PUCAI change scores also differentiated 
well among different categories (no change, small, moderate, large) of change in PGA. A 
small change in PUCAI (indicated with a 10 point change) gave a sensitivity and specificity 
of approximately 80%.
The moderately strong associations between PGA and PUCAI observed in our cross-
sectional and longitudinal analyses are in line with prior work, and not unexpected given 
that many clinicians base their PGA on a careful history, including many of the components 
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of the PUCAI. The weighted kappa, k = 0.733, observed here is consistent with previously 
published results by Lee et al (k = 0.71).12 The ICC observed here was slightly lower than 
that reported by Turner et al18 (72% versus 89%), likely owing to the diversity of practices 
and physicians included in this network, along with variable degrees of IBD expertise.
These findings have several important implications for clinical care. The high feasibility and 
validity of the PUCAI in routine clinical practice provide strong support for the use of this 
instrument as a clinical tool, including serving as a basis for inpatient and outpatient care 
algorithms. It is worth emphasizing that while PUCAI is not an objective measure of 
inflammation, like colonoscopy or non-invasive biochemical markers (i.e. calprotectin), it is 
a more standardized approach to measuring disease activity than PGA. Indeed, the wide 
variability (distribution) of PUCAI scores within categories of PGA depicted in the box plot 
figures illustrates the subjectivity of the PGA and underscores the importance of a more 
standardized, yet practical and feasible, measure such as PUCAI. The role of PUCAI in 
clinical care has been recently highlighted in study of hospitalized patients demonstrating 
that PUCAI scores on hospital days 3 and 5 of corticosteroid therapy can predict patients 
that are likely to fail corticosteroid therapy, and thus should proceed with salvage therapy (in 
this case infliximab) provides additional support for its use in clinical care.19
There are several limitations of our study. First, ImproveCareNow sites are a self-selected 
group of practices who participate in a voluntary quality improvement network and collect 
standardized data in the context of routine clinical care. Additionally, all centers receive data 
quality reports, including metrics on data completeness, and sites are encouraged to improve 
the quality of both data collection and clinical care. Hence, our findings may not be 
applicable to all pediatric GI practices. However, as mentioned above, the diversity of 
practices and IBD volume/expertise in the network supports the generalizability of our 
study. Furthermore, the paper-based or EHR clinic templates used in the network to can be 
easily embedded into the clinical workflow of any pediatric GI practice. Another limitation 
is the small sample size at the periphery of the distribution of the change in PGA categories 
(both large worsening and large improvement categories each had 5 patients). This is 
because these data were derived from an outpatient database, and thus few patients were 
classified as severe. (Patients with severe disease are more likely to be hospitalized). Thus, 
caution should be exercised when interpreting the results pertaining to these large changes. 
An additional limitation is the possibility of data entry errors, as would be expected in a 
clinical registry comprised of 2503 patients with UC and 11,734visits, which might account 
for some of the extreme outliers seen in our figures. Finally, it is possible that since the 
PUCAI items were recorded by the same physician that assigned the PGA, we may have 
overestimated the association between PUCAI and PGA. However, the PUCAI score itself 
was not routinely calculated by providers and therefore this should not affect the assignment 
of a PGA any more than taking a good patient history.
In this study, we did not evaluate associations between laboratory values and PUCAI, as the 
associations between these measures have been previously described as part of the original 
validation study by Turner et. al.18 Similarly, we did not evaluate associations between 
PUCAI and non-invasive markers of inflammation such as colonoscopy and calprotectin, 
given that the fundamental advantage of the PUCAI is that its non-invasive nature makes it 
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suitable for the repeated, often frequent, clinical assessments which are a necessary 
component of clinical care. Furthermore, in the PUCAI validation study, the observed 
correlation of the PUCAI with macroscopic mucosal inflammation was sufficiently strong to 
allow measurement of disease activity without endoscopic assessment.12,17 This is 
important, as obtaining frequent endoscopic assessment and/or measurement of calprotectin 
is neither practical nor cost-efficient.
In summary, this is the first large-scale, multicenter evaluation of the PUCAI used by 
hundreds of pediatric gastroenterologists among dozens of centers in a simulated routine 
(based on registry data) clinical practice setting in which we conclude that the PUCAI is 
highly feasible, valid and responsive to change. This study expands prior work as it 
examines the use of PUCAI in a much more diverse group of patients, providers and centers. 
This study demonstrated additional evidence to support the generalizability and ease of use 
of the PUCAI. These findings support the use of PUCAI as a clinical tool, as well as a 
research tool.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Boxplot depicting the distribution of Pediatric Ulcerative Colitis Activity Index (PUCAI) 
scores according to physician global assessment (PGA) categories. Within the boxplots, the 
“+” symbol denotes the mean activity index score for each category of disease severity, the 
vertical boxes depict the range of scores from the 25th to 75th percentile, and the horizontal 
hash mark in the middle of the vertical box represents median score. The mean PUCAI(± 1 
SD) for all patients whose PGA is in remission was 3.23 ± 6.52, 19.66 ± 14.32 for mild 
disease, 41.93 ± 19.52 for moderate disease, and 54.48 ± 23.92 for severe disease.
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Boxplot depicting the distribution of change in Pediatric Ulcerative Colitis Activity Index 
(PUCAI) according to the degree of change in Physician Global Assessment (PGA) 
categories.
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Table 1
The Pediatric Ulcerative Colitis Activity Index Components1
Item Points
1. Abdominal pain
 No pain 0
 Pain can be ignored 5
 Pain cannot be ignored 10
2. Rectal bleeding
 None 0
 Small amount only, in <50% of stools 10
 Small amount with most stools 20
 Large amount (>50% of stool content) 30
3. Stool consistency of most stools
 Formed 0
 Partially formed 5
 Completely unformed 10









 No limitation of activity 0
 Occasional limitation of activity 5
 Severe restricted activity 10
Sum of PUCAI 0–85
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Table 2
Patient Demographics at the Most Recent Visit
Variable n (%)
Total number of patients 2503
Gender
 Male 1237 (49.4)
Age (mean ± SD) 15.2 ± 4.1 years
Race/Ethnicity
 White 1920 (81.9)
 Black 199 (8.5)
 Hispanic or Latino 87 (3.7)
 Asian 42 (1.8)
 Other 97 (4.1)
Disease duration 3.7 ± 3.2 years
Paris Classification (n=1773 (70.8%))
 E1: ulcerative proctitis 154 (8.7)
 E2: left-sided (distal to splenic flexure) 330 (18.6)
 E3: extensive (hepatic flexure distally) 135 (7.6)
 E4: pancolitis (proximal to hepatic flexure) 1154 (65.1)
Laboratory studies
 Mean Hematocrit (n=1983) 38.4 ± 4.5 in %
 Mean ESR (n=1752) 14.0 ± 14.2 mm/h
 Mean CRP (n=1527) 1.3 ± 5.6 mg/dL
 Mean Albumin (n=1900) 4.3 ± 0.9 g/dL
PGA
 Remission 1703 (70.0)
 Mild 518 (21.3)
 Moderate 183 (7.5)
 Severe 30 (1.2)
Medications
 5-ASA 1776 (71.1)
 Prednisone 411 (16.5)
 6-MP/AZA 850 (34.0)
 Methotrexate 91 (3.7)
 Anti-TNFα 400 (16.0)
PGA = physician global assessment; 5-ASA = 5-aminosalicylates; 6-MP=6-mercaptopurine; AZA=azathioprine, biologics=infliximab, 
adalimumab, certolizumab






















Dotson et al. Page 13
Table 3
PUCAI Responsiveness Analysis
Median change in PUCAI (IQR)
a Improved (n = 69) 35 (−10 to 75)
a Stable (n = 1760) 0 (−5 to 5)
a Worsened (n = 45) −40 (−80 to 0)
b Responsiveness statistic [MID/SDunchanged] 1.18
Correlation with change in PGA 0.69 (p < 0.001)
a
Groups categorized based on change in PGA and the corresponding statistics represent the median with IQR in parentheses
b
SDunchanged is the standard deviation of change in PUCAI for all the patients whose PGA is unchanged; Effect sizes are defined as: 0.2–0.5 = 
small effect, 0.5–0.8 = moderate effect, and >0.8 = large effect
PUCAI = Pediatric Ulcerative Colitis Activity Index; IQR = interquartile range; MID=minimal important difference; SD = standard deviation; 
PGA = Physician Global Assessment
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